首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   244045篇
  免费   37719篇
  国内免费   2728篇
耳鼻咽喉   6095篇
儿科学   7721篇
妇产科学   4089篇
基础医学   15284篇
口腔科学   3184篇
临床医学   36442篇
内科学   65715篇
皮肤病学   8613篇
神经病学   24256篇
特种医学   10014篇
外国民族医学   3篇
外科学   55898篇
综合类   1309篇
现状与发展   72篇
一般理论   131篇
预防医学   14913篇
眼科学   5319篇
药学   7309篇
中国医学   111篇
肿瘤学   18014篇
  2024年   543篇
  2023年   5145篇
  2022年   2023篇
  2021年   5027篇
  2020年   7159篇
  2019年   4136篇
  2018年   9681篇
  2017年   8896篇
  2016年   10095篇
  2015年   10398篇
  2014年   18499篇
  2013年   19836篇
  2012年   12748篇
  2011年   13147篇
  2010年   14556篇
  2009年   17900篇
  2008年   12619篇
  2007年   11219篇
  2006年   13395篇
  2005年   10422篇
  2004年   9560篇
  2003年   7888篇
  2002年   7649篇
  2001年   4508篇
  2000年   3458篇
  1999年   3988篇
  1998年   4723篇
  1997年   4257篇
  1996年   3997篇
  1995年   3792篇
  1994年   2471篇
  1993年   2098篇
  1992年   1767篇
  1991年   1750篇
  1990年   1348篇
  1989年   1437篇
  1988年   1261篇
  1987年   1116篇
  1986年   1099篇
  1985年   980篇
  1984年   831篇
  1983年   765篇
  1982年   838篇
  1981年   674篇
  1980年   576篇
  1979年   396篇
  1978年   453篇
  1977年   498篇
  1975年   342篇
  1972年   346篇
排序方式: 共有10000条查询结果,搜索用时 250 毫秒
21.
22.
23.

Objective

Comparative survival between neoadjuvant chemotherapy and adjuvant chemotherapy for patients with cT2-4N0-1M0 non–small cell lung cancer has not been extensively studied.

Methods

Patients with cT2-4N0-1M0 non–small cell lung cancer who received platinum-based chemotherapy were retrospectively identified. Exclusion criteria included stage IV disease, induction radiotherapy, and targeted therapy. The primary end point was disease-free survival. Secondary end points were overall survival, chemotherapy tolerance, and ability of Response Evaluation Criteria In Solid Tumors response to predict survival. Survival was estimated using the Kaplan–Meier method, compared using the log-rank test and Cox proportional hazards models, and stratified using matched pairs after propensity score matching.

Results

In total, 330 patients met the inclusion criteria (n = 92/group after propensity-score matching; median follow-up, 42 months). Five-year disease-free survival was 49% (95% confidence interval, 39-61) for neoadjuvant chemotherapy versus 48% (95% confidence interval, 38-61) for adjuvant chemotherapy (P = .70). On multivariable analysis, disease-free survival was not associated with neoadjuvant chemotherapy or adjuvant chemotherapy (hazard ratio, 1.1; 95% confidence interval, 0.64-1.90; P = .737), nor was overall survival (hazard ratio, 1.21; 95% confidence interval, 0.63-2.30; P = .572). The neoadjuvant chemotherapy group was more likely to receive full doses and cycles of chemotherapy (P = .014/0.005) and had fewer grade 3 or greater toxicities (P = .001). Response Evaluation Criteria In Solid Tumors response to neoadjuvant chemotherapy was associated with disease-free survival (P = .035); 15% of patients receiving neoadjuvant chemotherapy (14/92) had a major pathologic response.

Conclusions

Timing of chemotherapy, before or after surgery, is not associated with an improvement in overall or disease-free survival among patients with cT2-4N0-1M0 non–small cell lung cancer who undergo complete surgical resection.  相似文献   
24.
25.
26.
Animal and human studies suggest fish oil and green tea may have protective effect on prostate cancer. Fatty acid synthase (FAS) has been hypothesized to be linked to chemoprotective effects of both compounds. This study evaluated the independent and joint effects of fish oil (FO) and green tea supplement (epigallocatechin-3-gallate, EGCG) on FAS and Ki-67 levels in prostate tissue. Through a double-blinded, randomized controlled trial with 2 × 2 factorial design, 89 men scheduled for repeat prostate biopsy following an initial negative prostate biopsy were randomized into either FO alone (1.9 g DHA + EPA/day), EGCG alone (600 mg/day), a combination of FO and EGCG, or placebo. We used linear mixed-effects models to test the differences of prostate tissue FAS and Ki-67 by immunohistochemistry between pre- and post-intervention within each group, as well as between treatment groups. Results did not show significant difference among treatment groups in pre-to-post-intervention changes of FAS (P = 0.69) or Ki-67 (P = 0.26). Comparing placebo group with any of the treatment groups, we did not find significant difference in FAS or Ki-67 changes (all P > 0.05). Results indicate FO or EGCG supplementation for a short duration may not be sufficient to produce biologically meaningful changes in FAS or Ki-67 levels in prostate tissue.  相似文献   
27.
28.
29.
30.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号